Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
David Jones(Memorial Sloan Kettering Cancer Center), Gideon M. Hirschfield(University Health Network), Norman Gitlin(NYU Langone Health), Hemant Shah(University Health Network), John M. Vierling(Baylor College of Medicine), Christopher L. Bowlus(University of California, Davis), George Mells(Cambridge University Hospitals NHS Foundation Trust), Marek Hartleb(Medical University of Silesia), Virginia Clark, Charles A. McWherter(University Health Network), Stuart C. Gordon(United States Department of Veterans Affairs), Alexandra Steinberg(CymaBay Therapeutics (United States)), Ewa Janczewska, Pol Boudes(CymaBay Therapeutics (United States)), B. Freilich(Kansas City Research Institute), Cynthia Levy(University of Miami), Peter Buggisch(Institute for Interdisciplinary Medicine), Andreas E. Kremer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Mark G. Swain(University of Calgary), David Sheridan(University Hospitals Plymouth NHS Trust), Joseph A. Odin(University of Pittsburgh), Fedja A. Rochling(University of South Florida), Mónika Varga(CymaBay Therapeutics (United States)), Yun‐Jung Choi(CymaBay Therapeutics (United States)), Mark Jonas(Ohio Gastroenterology and Liver Institute), John H. Smith(Digestive & Liver Disease Specialists), M A Wörns(Johannes Gutenberg University Mainz), David Bernstein(University of Florida), Bruce R. Bacon(Saint Louis University), Michael Galambos, Yvonne Döerffel(Charité - Universitätsmedizin Berlin), Heinz Hartmann(Praxis für Humangenetik), Harinder Chera(CymaBay Therapeutics (United States)), Robert L. Martin(CymaBay Therapeutics (United States)), Mitchell L. Shiffman(Bon Secours Health System)
Cited by 186
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k